Navigation Links
N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201
Date:5/5/2008

BOULDER, Colo., May 5 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target endogenous s-nitrosothiols, announced today that it has successfully completed Phase I study of N30-201 in patients with mild to moderate asthma, as well as healthy volunteers. N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including Cystic Fibrosis and asthma.

"We are pleased to have completed the Phase 1 set of human studies of N30-201. We believe that N30-201 could be an important therapy for the treatment of many respiratory diseases. Determining the safety of acute administration of N30-201 to asthmatic, as well as healthy human subjects, is an important step." commented Charles Scoggin, M.D., Chairman of N30 Pharma.

The primary endpoint of the study is patient safety and characterization of adverse events, but the company collected pharmacokinetic and pharmacodynamic data of ascending doses of N30-201, including effects on the airway.

About N30-201

N30-201 is a proprietary nebulized formulation of s-nitrosoglutathione (GSNO), an endogenous bronchodilatory molecule that serves as a critical store of nitric oxide (NO) bioactivity in the human airway.

About N30 Pharma

N30 Pharma is developing s-nitrosothiol therapies for critical unmet needs in important respiratory and cardiovascular diseases. S-nitrosothiols are endogenous molecules which store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone. N30's drug development strategy focuses on administration of GSNO to the human airway, and the development of inhibitors of GSNO reductase. GSNO reductase is the key enzyme in the body that breaks down GSNO. These approaches allow N30 to deliver targeted, long lasting, physiologically relevant doses of s-nitrosothiols to target systems. N30 is a privately held company headquartered in Boulder, Colorado.


'/>"/>
SOURCE N30 Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
2. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
3. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
4. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
5. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
7. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
10. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
11. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)...  The U.S. Food and Drug Administration today granted ... adults and pediatric patients 12 years and older with ... not received prior chemotherapy. This is the first FDA-approved ... skin cancer. "While skin cancer is one ... form called Merkel cell cancer have not had an ...
(Date:3/23/2017)... AUSTIN, Texas , March 23, 2017 /PRNewswire/ ... www.digitalpharmacist.com ), a rapidly growing digital ... PocketRx, a mobile app that allows patients to ... including multi-store locations such as Denver Health Pharmacy, ... app. The acquisition helps Digital Pharmacist accelerate its ...
(Date:3/23/2017)... , March 23, 2017  Interpace Diagnostics Group, ... a fully integrated commercial company that provides clinically ... announced that it has entered into agreements to ... RedPath Shareholders ("RedPath") and concurrently terminate its royalty ... outstanding secured debt to RedPath amounting to $9.34 ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... ... , ... The MBI “Hall of Fame” recognizes the contributions of those whose careers are or ... the careers of all others involved. , On Monday, March 21st, 2017 Laurie ... of Fame. The induction took place during the World of Modular – Award Gala ...
(Date:3/23/2017)... TX (PRWEB) , ... March 23, 2017 , ... March ... organs that pack a punch when it comes to maintaining good health. Every day, ... 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating fluid ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Angeles based healthcare technology company California Healthcom Group (CHG). , The HUG ... healthcare arena. With headquarters in California, CHG is a growing, internationally recognized healthcare ...
Breaking Medicine News(10 mins):